Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback